Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ
5.74
-1.27 (-18.12%)
Closed
Oct 23, 2026
Day's Range
5.016.76
52 wk Range
5.0118.31
Financial Statements - PHAT - Phathom Pharmaceuticals, Inc.
Revenue
175.11M▲ 216.9%
Net Income
-221.24M▲ 33.8%Net Margin -126.3%
EBITDA
-152.49M▲ 41.7%
Free Cash Flow
-167.00M▲ 37.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 175.11M | 55.25M | 682K | 0 | 0 | 0 |
| Cost of Goods | 22.59M | 7.97M | 167K | 0 | - | - |
| Gross Profit | 152.51M | 47.27M | 515K | 0 | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -159.98M | -277.46M | -167.31M | -172.44M | -135.08M | -125.66M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -190K | -8K | -188K | -110K | -2.05M | 87K |
| Pre Tax Income | -221.24M | -334.32M | -201.59M | -197.72M | -143.88M | -129.06M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -221.24M | -334.32M | -201.59M | -197.72M | -143.88M | -129.06M |
| EPS Basic | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 |
| EPS Diluted | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 |
| Basic Shares Outstanding | 72.91M | 63.17M | 51.28M | 39.11M | 37M | 33.22M |
| Diluted Shares Outstanding | 72.91M | 63.17M | 51.28M | 39.11M | 37M | 33.22M |
| Ebit | -153.13M | -262.31M | -159.62M | -170.41M | -137.09M | -124.48M |
| Ebitda | -152.49M | -261.52M | -159.04M | -169.79M | -136.57M | -124.25M |
| Net Income Continuous Operations | -221.24M | -334.32M | -201.59M | -197.72M | -143.88M | -129.06M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
